Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection

Canadian Journal of Cardiology

Volumn 29, Issue 2, 2013, Pages 182-195

  Exner, Derek V ^a   Birnie, David H ^b   Moe, Gordon ^c   Thibault, Bernard ^d   Philippon, François ^e   Healey, Jeffrey S ^f   Tang, Anthony S L ^b,g   Larose, Éric ^e   Parkash, Ratika ^h  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL EFFECTIVENESS; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE PACING; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL SOCIETY; PACEMAKER; PATIENT SELECTION; PRACTICE GUIDELINE; QRS COMPLEX; RISK BENEFIT ANALYSIS; SINUS RHYTHM;

EID: 84872698697     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.10.006     Document Type: Article

References (117)

1. Tracking Heart Disease and Stroke in Canada Public Health Agency of Canada, Accessed September 23, 2012. http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf.
2. Ghio S., Constantin C., Klersy C., et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J 2004, 25:571-578.
3. Nelson G.S., Berger R.D., Fetics B.J., et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block [erratum in 2001;103:476]. Circulation 2000, 102:3053-3059.
4. Linde C., Abraham W.T., Gold M.R., Daubert C. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol 2010, 56:1826-1831. REVERSE Study Group.
5. Auricchio A., Stellbrink C., Sack S., et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002, 39:2026-2033.
6. Salukhe T.V., Francis D.P., Morgan M., et al. Mechanism of cardiac output gain from cardiac resynchronization therapy in patients with coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 2006, 97:1358-1364.
7. Wells G., Parkash R., Healey J.S., et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ 2011, 183:421-429.
8. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 22:23-45.
9. Malcom J., Arnold O., Howlett J.G., et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure-2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol 2008, 24:21-40.
10. Guyatt G., Oxman A.D., Akl E.A., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011, 64:383-394.
11. Gillis A.M., Skanes A.C. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: implementing GRADE and achieving consensus. Can J Cardiol 2011, 27:27-30. CCS Atrial Fibrillation Guidelines Committee.
12. McKelvie R.S., Moe G.W., Cheung A., et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011, 27:319-338.
13. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
14. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
15. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. New Engl J Med 2009, 361:1329-1338.
16. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. New Engl J Med 2010, 363:2385-2395.
17. Fornwalt B.K., Sprague W.W., BeDell P., et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010, 121:1985-1991.
18. Exner D.V., Auricchio A., Singh J.P. Contemporary and future trends in cardiac resynchronization therapy to enhance response. Heart Rhythm 2012, 9(8 suppl):S27-S35.
19. Lozano I., Bocchiardo M., Achtelik M., et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing Clin Electrophysiol 2000, 23(11 pt 2):1711-1712.
20. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. New Engl J Med 2001, 344:873-880.
21. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845-1853.
22. Young J.B., Abraham W.T., Smith A.L., et al. Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure: The MIRACLE ICD Trial. JAMA 2003, 289:2685-2694.
23. Abraham W.T., Young J.B., León A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004, 110:2864-2868.
24. Linde C., Abraham W.T., Gold M.R., et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008, 52:1834-1843.
25. Summary of Safety and Effectiveness Data. Dual Chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy. St. Jude Medical Epic HF System including the Epic HF Model V-338 cardiac resynchronization therapy defibrillator, the Aescula LV model 1055K lead, the QuickSite LV model 1056K lead, and the model 3307, v4.5m programmer software US Food and Drug Administration, Accessed September 23, 2012. http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030054b.pdf.
26. Summary of Safety and Effectiveness Data. Cardiac Resynchronization Therapy - Pacemaker (CRT-P)System. St. Jude Medical Frontier model 5508L and Frontier II model 5586 cardiac resynchronization therapy pacemakers (CRT-P) supported on the model 3510 programmer platforms with the model 3307, v4.8m programmer software US Food and Drug Administration, Accessed September 23, 2012. http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030035S003b.pdf.
27. Higgins J.P., Altman D.G., Gøtzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
28. Linde C. Cardiac resynchronization therapy in mild heart failure. Europace 2009, 11(suppl 5):v72-v76.
29. Adabag S., Roukoz H., Anand I.S., Moss A.J. Cardiac resynchronization therapy in patients with minimal heart failure a systematic review and meta-analysis. J Am Coll Cardiol 2011, 58:935-941.
30. Poole J.E., Gleva M.J., Mela T., et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010, 122:1553-1561.
31. Barsheshet A., Moss A.J., Huang D.T., McNitt S., Zareba W., Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012, 59:2075-2079.
32. Kramer D.B., Friedman P.A., Kallinen L.M., et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012, 9:42-46.
33. van Rees J.B., Borleffs C.J., van Welsenes G.H., et al. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score. Heart 2012, 98:872-877.
34. Sheldon R., Connolly S., Krahn A., Roberts R., Gent M., Gardner M. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000, 101:1660-1664.
35. Exner D.V., Sheldon R.S., Pinski S.L., Kron J., Hallstrom A. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy?. Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001, 141:99-104.
36. Moss A.J., Fadl Y., Zareba W., Cannom D.S., Hall W.J. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001, 88:516-520. Defibrillator Implantation Trial Research Group.
37. Bogale N., Priori S., Gitt A., et al. The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. Europace 2011, 13:1445-1453.
38. Dickstein K., Vardas P.E., Auricchio A., et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010, 31:2677-2687.
39. Neyt M., Stroobandt S., Obyn C., et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open 2011, 1:e000276.
40. Owen A. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2006, 27:1125. author reply 1125-6.
41. Yao G., Freemantle N., Calvert M.J., Bryan S., Daubert J.C., Cleland J.G. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007, 28:42-51.
42. Riedlbauchová L., Cihák R., Bytesník J., et al. Optimization of right ventricular lead position in cardiac resynchronisation therapy. Eur J Heart Fail 2006, 8:609-614.
43. Bulava A., Lukl J. Similar long-term benefits conferred by apical versus mid-septal implantation of the right ventricular lead in recipients of cardiac resynchronization therapy systems. Pacing Clin Electrophysiol 2009, 32(suppl 1):S32-S37.
44. Haghjoo M., Bonakdar H.R., Jorat M.V., et al. Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure. Europace 2009, 11:356-363.
45. Khan F.Z., Salahshouri P., Duehmke R., et al. The impact of the right ventricular lead position on response to cardiac resynchronization therapy. Pacing Clin Electrophysiol 2011, 34:467-474.
46. Stockinger J., Staier K., Schiebeling-Römer J., Keyl C. Acute hemodynamic effects of right and left ventricular lead positions during the implantation of cardiac resynchronization therapy defibrillators. Pacing Clin Electrophysiol 2011, 34:1537-1543.
47. Kristiansen H.M., Vollan G., Hovstad T., Keilegavlen H., Faerestrand S. A randomized study of haemodynamic effects and left ventricular dyssynchrony in right ventricular apical vs. high posterior septal pacing in cardiac resynchronization therapy. Eur J Heart Fail 2012, 14:506-516.
48. Thébault C., Donal E., Meunier C., et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J 2012, 33:2662-2671.
49. Derval N., Steendijk P., Gula L.J., et al. Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites. J Am Coll Cardiol 2010, 55:566-575.
50. Bedi M., Suffoletro M., Tanabe M., Gorcsan J., Saba S. Effect of concordance between sites of left ventricular pacing and dyssynchrony on acute electrocardiographic and echocardiographic parameters in patients with heart failure undergoing cardiac resynchronization therapy. Clin Cardiol 2006, 29:498-502.
51. Merchant F.M., Heist E.K., McCarty D., et al. Impact of segmental left ventricle lead position on cardiac resynchronization therapy outcomes. Heart Rhythm 2010, 7:639-644.
52. Becker M., Kramann R., Franke A., et al. Impact of left ventricular lead position in cardiac resynchronization therapy on left ventricular remodelling. A circumferential strain analysis based on 2D echocardiography. Eur Heart J 2007, 28:1211-1220.
53. Ypenburg C., van Bommel R.J., Delgado V., et al. Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. J Am Coll Cardiol 2008, 52:1402-1409.
54. Becker M., Altiok E., Ocklenburg C., et al. Analysis of LV lead position in cardiac resynchronization therapy using different imaging modalities. JACC Cardiovasc Imaging 2010, 3:472-481.
55. Nakamae H., Tsumura K., Hino M., Hayashi T., Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000, 355:805-806.
56. Singh J.P., Klein H.U., Huang D.T., et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011, 123:1159-1166.
57. Kumar P., Blendea D., Nandigam V., Moore S.A., Heist E.K., Singh J.P. Assessment of the post-implant final left ventricular lead position: a comparative study between radiographic and angiographic modalities. J Interv Card Electrophysiol 2010, 29:17-22.
58. Rickard J., Ingelmo C., Sraow D., et al. Chest radiography is a poor predictor of left ventricular lead position in patients undergoing cardiac resynchronization therapy: comparison with multidetector computed tomography. J Interv Card Electrophysiol 2011, 32:59-65.
59. Khan F.Z., Virdee M.S., Palmer C.R., et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012, 59:1509-1518.
60. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006, 114:2766-2772.
61. Arshad A., Moss A.J., Foster E., et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011, 57:813-820.
62. Sipahi I., Carrigan T.P., Rowland D.Y., Stambler B.S., Fang J.C. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011, 171:1454-1462.
63. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [erratum in 2005;352:2146]. N Engl J Med 2005, 352:225-237.
64. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998, 32:695-703.
65. Pozzoli M., Cioffi G., Traversi E., Pinna G.D., Cobelli F., Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998, 32:197-204.
66. Crijns H.J., Tjeerdsma G., de Kam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000, 21:1238-1245.
67. Leclercq C., Walker S., Linde C., et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002, 23:1780-1787.
68. Mullens W., Grimm R.A., Verga T., et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 2009, 53:765-773.
69. Ritter P., Padeletti L., Gillio-Meina L., Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. Europace 1999, 1:126-130.
70. Hayes D.L., Boehmer J.P., Day J.D., et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011, 8:1469-1475.
71. Wilton S.B., Leung A.A., Ghali W.A., Faris P., Exner D.V. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2011, 8:1088-1094.
72. Gasparini M., Auricchio A., Metra M., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008, 29:1644-1652.
73. Kamath G.S., Cotiga D., Koneru J.N., et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol 2009, 53:1050-1055.
74. Healey J.S., Hohnloser S.H., Exner D.V., et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012, 5:566-570.
75. Bilchick K.C., Kamath S., DiMarco J.P., Stukenborg G.J. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010, 122:2022-2030.
76. Bogale N., Priori S., Cleland J.G., et al. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur J Heart Fail 2012, 14:61-73.
77. Gervais R., Leclercq C., Shankar A., et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009, 11:699-705.
78. Nery P.B., Ha A.C., Keren A., Birnie D.H. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm 2011, 8:1083-1087.
79. Zareba W., Klein H., Cygankiewicz I., et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011, 123:1061-1072.
80. Gold M.R., Thébault C., Linde C., et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study. Circulation 2012, 126:822-829.
81. Haghjoo M., Bagherzadeh A., Farahani M.M., Haghighi Z.O., Sadr-Ameli M.A. Significance of QRS morphology in determining the prevalence of mechanical dyssynchrony in heart failure patients eligible for cardiac resynchronization: particular focus on patients with right bundle branch block with and without coexistent left-sided conduction defects. Europace 2008, 10:566-571.
82. Fantoni C., Kawabata M., Massaro R., et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 2005, 16:112-119. discussion 120-1.
83. Lewinter C., Torp-Pedersen C., Cleland J.G., Køber L. Right and left bundle branch block as predictors of long-term mortality following myocardial infarction. Eur J Heart Fail 2011, 13:1349-1354.
84. Rickard J., Bassiouny M., Cronin E.M., et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. Am J Cardiol 2011, 108:1576-1580.
85. Gillis A.M., Pürerfellner H., Israel C.W., et al. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. Pacing Clin Electrophysiol 2006, 29:697-705.
86. Milasinovic G., Sperzel J., Smith T.W., et al. Reduction of RV pacing by continuous optimization of the AV interval. Pacing Clin Electrophysiol 2006, 29:406-412.
87. Dilaveris P., Pantazis A., Giannopoulos G., Synetos A., Gialafos J., Stefanadis C. Upgrade to biventricular pacing in patients with pacing-induced heart failure: can resynchronization do the trick?. Europace 2006, 8:352-357.
88. Ermis C., Seutter R., Zhu A.X., et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2005, 46:2258-2263.
89. Eldadah Z.A., Rosen B., Hay I., et al. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm 2006, 3:435-442.
90. Yannopoulos D., Lurie K.G., Sakaguchi S., et al. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 2007, 50:1246-1251.
91. Leon A.R., Greenberg J.M., Kanuru N., et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002, 39:1258-1263.
92. Wokhlu A., Rea R.F., Asirvatham S.J., et al. Upgrade and de novo cardiac resynchronization therapy: impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm 2009, 6:1439-1447.
93. Adelstein E.C., Saba S. Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am J Cardiol 2009, 103:238-242.
94. Witte K.K., Pipes R.R., Nanthakumar K., Parker J.D. Biventricular pacemaker upgrade in previously paced heart failure patients-improvements in ventricular dyssynchrony. J Card Fail 2006, 12:199-204.
95. Fröhlich G., Steffel J., Hürlimann D., et al. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. Eur Heart J 2010, 31:1477-1485.
96. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002, 288:3115-3123.
97. Doshi R.N., Daoud E.G., Fellows C., et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005, 16:1160-1165.
98. Yu C.M., Chan J.Y., Zhang Q., et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. New Engl J Med 2009, 361:2123-2134.
99. Curtis A.B., Adamson P.B., Chung E., Sutton M.S., Tang F., Worley S. Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale. J Cardiovasc Electrophysiol 2007, 18:965-971.
100. Curtis A.B. Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block (BLOCK HF Study) Paper presented at: American Heart Association Scientific Sessions 2012, Late Breaking Clinical Trials. November 4-6, 2012; Los Angeles, CA, Accessed November 7, 2012. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_446560.pdf.
101. Bax J.J., Molhoek S.G., van Erven L., et al. Usefulness of myocardial tissue Doppler echocardiography to evaluate left ventricular dyssynchrony before and after biventricular pacing in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2003, 91:94-97.
102. Yu C.M., Yang H., Lau C.P., et al. Regional left ventricle mechanical asynchrony in patients with heart disease and normal QRS duration: implication for biventricular pacing therapy. Pacing Clin Electrophysiol 2003, 26(2 pt 1):562-570.
103. Szulik M., Tillekaerts M., Vangeel V., et al. Assessment of apical rocking: a new, integrative approach for selection of candidates for cardiac resynchronization therapy. European J Echocardiogr 2010, 11:863-869.
104. Achilli A., Peraldo C., Sassara M., et al. Prediction of response to cardiac resynchronization therapy: the selection of candidates for CRT (SCART) study. Pacing Clin Electrophysiol 2006, 29(suppl 2):S11-S19.
105. Yu C.M., Fung J.W., Zhang Q., et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 2004, 110:66-73.
106. Chung E.S., Leon A.R., Tavazzi L., et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008, 117:2608-2616.
107. Tanaka H., Nesser H.J., Buck T., et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. Eur Heart J 2010, 31:1690-1700.
108. Marsan N.A., Henneman M.M., Chen J., et al. Left ventricular dyssynchrony assessed by two three-dimensional imaging modalities: phase analysis of gated myocardial perfusion SPECT and tri-plane tissue Doppler imaging. Eur J Nucl Med Mol Imaging 2008, 35:166-173.
109. White J.A., Yee R., Yuan X., et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006, 48:1953-1960.
110. Bleeker G.B., Kaandorp T.A., Lamb H.J., et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006, 113:969-976.
111. Chalil S., Foley P.W., Muyhaldeen S.A., et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace 2007, 9:1031-1037.
112. Westenberg J.J., Lamb H.J., van der Geest R.J., et al. Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy: head-to-head comparison between tissue doppler imaging and velocity-encoded magnetic resonance imaging. J Am Coll Cardiol 2006, 47:2042-2048.
113. Reichek N. MRI myocardial tagging. J Magn Reson Imaging 1999, 10:609-616.
114. Bilchick K.C., Dimaano V., Wu K.C., et al. Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging 2008, 1:561-568.
115. Sciagrà R., Giaccardi M., Porciani M.C., et al. Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med 2004, 45:164-168.
116. Henneman M.M., Chen J., Dibbets-Schneider P., et al. Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT?. J Nucl Med 2007, 48:1104-1111.
117. Girsky M.J., Shinbane J.S., Ahmadi N., Mao S., Flores F., Budoff M.J. Prospective randomized trial of venous cardiac computed tomographic angiography for facilitation of cardiac resynchronization therapy. Pacing Clin Electrophysiol 2010, 33:1182-1187.